The following information is exclusively reserved for physicians practicing in Austria, the Netherlands, Spain, and Switzerland where the Zio™ monitor ECG monitoring service is currently authorised and made available for use in accordance with local regulatory requirements.

Learn more
Search

Precision Brought to Your Practice

Zio™ ECG monitors and the iRhythm™ end-to-end monitoring service deliver highly accurate, clinically actionable data1-3 to the world of cardiology and electrophysiology.

Physician looking at tablet

Streamlined cardiac monitoring made easier

Our goal is to help simplify the cardiac monitoring experience end to end. The iRhythm monitoring service provides you with highly accurate data you can trust, so you can make the right diagnosis the first time.1-3

Remarkable long-term continuous monitoring (LTCM) outcomes

  • 57% more arrhythmia events detected vs. 24-hour Holter monitors4-7
  • 2.6x greater detection of atrial fibrillation v. usual care5-6,8-9
  • 99% usable recording5,7,10-11

Astounding patient compliance and satisfaction

  • 99% patient compliance for continuous, uninterrupted ECG recording3,7,12
  • 81% of patients preferred wearing a Zio LTCM device for 
14 days over a 24-hour Holter monitor4,6-7
  • Minimal disruption2-3 to patients’ daily activities with no maintenance or battery changes required13

Enhanced provider efficiency

  • 99% physician agreement with the Zio™ end-of-wear report3,7,14-15
  • Robust reports leveraging iRhythm's advanced service and deep-learned AI algorithm (ZEUS)16-19
  • Convenient report access with ZioSuite™ web portal.

Reduced cost of care

  • Zio long-term continuous monitoring (LTCM) for up to 14 days is associated with the lowest likelihood of repeat testing compared to 48-hour (traditional) Holter, event recorder and other LTCM's2,5-7,20-23

Proven precision

The value of the iRhythm monitoring service has been demonstrated in over 135 original scientific research manuscripts.1

Clinical Article
Reynolds et al, American Heart Journal, 2023.
Comparative Effectiveness of ACM Strategies (CAMELOT Study)
A retrospective study of variations in ACM strategies, clinical outcomes and health care costs in diagnostic-naïve patients
Read more
Clinical Article
Eysenck et al., Journal of Interventional Cardiac Electrophysiology, 2019.
Comparison of 4 ACMs to Permanent Pacemaker AF Detection
A prospective, randomized study to compare ACM AF burden and AF episodes in patients implanted with a pacemaker with known AF
Read more
Clinical Article
Rosenberg et al., Pacing and Clinical Electrophysiology, 2013.
Noninvasive Continuous Monitor in Management of AF
A prospective head-to-head comparison of Zio device vs. 24-hour Holter monitors in patients with PAF
Read more
Zio monitor Sample Report - Europe

End-of-wear reports with 99% physician agreement3,7,14-15

The Zio™ end-of-wear report is generated by a CE-marked and FDA-cleared, advanced AI, Zio™ ECG Utilization Service (ZEUS) system that can detect 13 different types of arrhythmias, plus sinus rhythm and artifacts, and is curated and verified by Qualified ECG Specialists (QES).16-19

  • The algorithm can classify a broad range of distinct arrhythmias with high diagnostic performance similar to that of cardiologists17
  • End-of-wear report provides a comprehensive analysis based on the full wear period16-19
  • The Zio report™ provides you with a rich summary of clinically actionable cardiac events on the first page — and an easy-to-navigate deep dive for all the intricate details captured
View the Zio report
CE-marked and FDA cleared AI
Physician looking at computer

Seamless EHR integration

Reduce staff burden, automate processes, and accelerate patient care pathways by integrating the iRhythm monitoring service directly into your electronic health record (EHR).

  • Enables workflow efficiency gains
  • Supports shift to value-based care
  • Compatible with all major EHR systems
  • Scalable population health management
Simplify your workflow
ZioSuite image

Everything you need, all in one place

ZioSuite™ is an elegant, easy-to-use interface with smart productivity features that allow you to enroll, track, and manage patients, and interpret reports with ease, all from your computer.

  • Patient registration
  • Online interpretation
  • Device tracking
  • Account history management
Learn about ZioSuite™
Patient wearing iRhythm monitor

Made exactly for patients like yours

Compared to Holter monitoring, the Zio LTCM device was well tolerated and allowed for longer continuous monitoring — resulting in an improvement in clinical accuracy, and a meaningful change in clinical management.5-6,22-23,26

Easy to use
91% of patients who wore the Zio monitor™ reported it was easy to use and 90% would wear again.7,10,27
Designed for every day
Breathable,28-29 pliable,7,13,27 and waterproof design28-29 for daily activities7,13,27 - no electrodes to reposition or batteries to recharge.13
Simple to apply and to wear
The small20 and comfortable7,13,27 monitor leads to astounding 99% patient compliance.3,7,12
Preferred by patients
81% of patients preferred wearing a Zio LTCM device for 14 days over a 24-hour Holter monitor.4,6-7
Find patient support

Medical Affairs

Our Medical Affairs team partners directly with our customers on clinical science, research ideas, educational opportunities, and grant requests. Browse our collection of offerings.
Discover more

Continue the conversation

The Zio™ Service helps you detect arrhythmias earlier, reduce administrative burden, and enhance patient experience — all through a single, streamlined platform.

 

Connect with an iRhythm specialist today to discover how the Zio service can fit into your workflow.

Continue the conversation
Man with child on his shoulders
  1. Data on file. iRhythm Technologies, 2026.  
  2. Based on the US market data using Zio ECG monitors.  
  3. Zio service provides continuous, uninterrupted recording and a comprehensive end-of-wear report. 
  4. Barrett et al. Comparison of 24-hour Holter Monitoring with 14-day Novel Adhesive Patch Electrocardiographic Monitoring. The American Journal of Medicine. 2014;127(1):95.e11-95.e17.  
  5. Zio LTCM service refers to Zio XT and Zio monitor service.   
  6. Based on previous generation Zio XT device data. Zio monitor utilizes the same operating principles and ECG algorithm. Additional data on file.  
  7. Based on the US data. 
  8. Steinhubl et al. Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation. JAMA. 2018;320(2):146. doi:https://doi.org/10.1001/jama.2018.8102 
  9. This is a US study in which US participants received their Zio device by postal mail, and self-applied the patch.  Follow-up events, including the hospitalizations mentioned, were derived from analyzing healthcare/medical claims database for the study participants. 
  10. Data on file. iRhythm Technologies, 2024. 
  11. Analyzable time is based off median values for a 14-day prescription. 
  12. Data on file. iRhythm Technologies, 2022.  
  13. Zio monitor Instructions for Use. iRhythm Technologies, 2023. 
  14. Based on a review of all online Zio XT, Zio monitor, and Zio AT end-of-wear reports. Data on file. iRhythm Technologies, 2023. 
  15. 99% of physicians agree with the comprehensive end-of-wear report. Based on a review of all online Zio XT, Zio monitor, and Zio AT end-of-wear reports. Data on file. iRhythm Technologies, 2023. 
  16. Data on file. iRhythm Technologies, 2020.  
  17. Hannun et al. Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network. Nat Med. 2019;25:65-69. https://doi.org/10.1038/s41591-018-0268-3 
  18. Deep learned algorithm is only available in the United States, European Union, Switzerland, United Kingdom, and Japan.  
  19. FDA 510K clearance, CE mark, UKCA mark, and PMDA-approval. 
  20. Reynolds et al. Comparative effectiveness and healthcare utilization for ambulatory cardiac monitoring strategies in Medicare beneficiaries. Am Heart J. 2024;269:25–34. https://doi.org/10.1016/j.ahj.2023.12.002 
  21. Diagnostic yield was assessed based upon the evaluation of specified arrhythmias, which refer to an arrhythmia encounter diagnosis as per Hierarchical Condition Categories (HCC) 96.   
  22. Contraindications: Do not use the Zio monitor for critical care patients or for patients with symptomatic episodes where instance variations in cardiac performance could result in immediate danger to the patients or when real-time or in-patient monitoring should be prescribed. (Refer to the Zio monitor Instructions for Use for the full list of contraindications.)  
  23. Zio monitor and ZEUS are CE-marked. 
  24. Hannun et al. Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network. Nat Med. 2019;25:65-69. https://doi.org/10.1038/s41591-018-0268-3 
  25. Baseline reports, daily reports, and transmission reports are not electronically transmitted from iRhythm to EHR systems. They are available in ZioSuite. 
  26. Rosenberg et al. Use of a noninvasive continuous monitoring device in the management of Atrial Fibrillation: A pilot study. Pacing and Clinical Electrophysiology. 2012;36(3):328-333. doi:10.1111/pace.12053 
  27. Battisti et al. Abstract 4141717: Feasibility of point-of-wear patient satisfaction surveys to validate patient-centered product enhancements: results from over 300,000 patients for long-term ambulatory cardiac monitoring. Circulation. 2024;150:A4141717. doi:10.1161/circ.150.suppl_1.4141717. https://www.ahajournals.org/doi/abs/10.1161/circ.150.suppl_1.4141717 
  28. Data on file. iRhythm Technologies, 2017, 2023. 
  29. The Zio monitor device should not be submerged in water. During a bath, keep the device above water. Please refer to the Zio monitor labeling instructions or Patient Guide for the full set of details

 

The Zio™ service is a long-term continuous ambulatory cardiac monitoring service. It consists of the Zio™ monitor that collects beat-to-beat ECG data and can be worn for up to 14 days; the Zio™ ECG Utilization Service (ZEUS) System deep learned algorithm, which detects arrhythmias. The data is reviewed and curated by a team of Qualified ECG Specialists (QES) to provide the final patient report.

For indications for use, warnings & contraindications, visit here.

iRhythm, Zio, Zio monitor, and ZioSuite are trademarks of iRhythm Technologies, Inc. ©2024 All rights reserved.

Zio™ monitor and ZEUS are CE-marked (CE2797).

Zio monitor, ZEUS, and Zio service are currently available in Austria, the Netherlands, Spain & Switzerland.

For further regulatory information visit here.

WEB0216.01

Contact us